Full-Time

Lead Product Manager

Eucalyptus

Eucalyptus

501-1,000 employees

Global telehealth platform offering digital clinics

No salary listed

New South Wales, Australia

In Person

On-site at Eucalyptus HQ, New South Wales, Australia.

Category
Product (1)
Required Skills
UI/UX Design
Product Management
Data Analysis

Get referred to Eucalyptus

See people who can refer or advise you

Requirements
  • You’ve likely built your experience over 5+ years across Product Management, with ownership of consumer-facing, high-engagement product domains
  • Professional Services (like top-tier management consultancies, legal firms) or other roles within a high-growth startup, or founded your own startup
  • We are open to various backgrounds; AI background not required but welcome and the role values strong analytical and product thinking
Responsibilities
  • Lead The Vision & Roadmap: Working with the Chief Commercial Officer & Principal Product Manager, shape the vision for Insights that power our patient’s proactive care. Set the direction and define the bets we make
  • Execute Quickly, Deliver Globally: Design experiences that make a patient feel their progress and drive engagement, habit formation and long-term retention. Take products from idea to impact and ship them to patients across every market Juniper and future brands operate in. You'll own delivery end-to-end and stay close to the craft
  • Drive Patient Outcomes, Engagement & Retention: Own your key engagement and retention metrics, connecting product decisions to real health outcomes and commercial impact. You’ll use data and patient insight to understand what's working and what needs to change.
  • Raise Bar On Craft: Partner closely with design and clinicians to set a high standard for quality, so every insight feels intuitive, trustworthy and distinctly Juniper.
  • Cross-Functional Collaboration: Align clinicians, data, design and engineering, and partner with senior stakeholders to unblock execution and deliver cohesive end-to-end outcomes.
Desired Qualifications
  • First-principles problem solver — You are able to break ambiguous problems down, build a clear and focussed strategy around it, and able to take something from idea to impact while applying clear judgement on tradeoffs along the way
  • Commercial & analytical rigour — You are laser-focused on delivering outcomes. You design for outcomes you can measure, interpret both quantitative and qualitative signal, and won't mistake motion for progress
  • Product sense — You have a real instinct and empathy for what makes a person feel something. You can tell the difference between a feature that's “works” and one that lands, and you have a strong intuition for what makes products feel delightful, trustworthy and easy to use
  • Ownership and comfort with ambiguity — you're energised by ambiguous, high-impact, undefined problems, and you've got a track record of navigating and leading through ambiguity
  • Influence without authority — You have a track record of building credibility and follower-ship amongst teams and stakeholders, built off the consistency and quality of your judgement, storytelling ability, and long-term relationship building

Eucalyptus.vc runs digital healthcare clinics as a global telehealth service focused on patient-first care. Patients connect with certified practitioners for remote consultations, treatments, and ongoing care entirely through the online platform. The service provides end-to-end care in one digital ecosystem, from initial visit to follow-up, with revenue from fees for these clinical services. The company aims to make safe, effective care accessible worldwide by leveraging its global team of over 400 professionals to operate the clinics.

Company Size

501-1,000

Company Stage

Acquired

Total Funding

$139.7M

Headquarters

Sydney, Australia

Founded

2019

Get referred to Eucalyptus

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Hims & Hers closed the acquisition on 2026-06-02, validating Eucalyptus's scale.
  • Run-rate revenue exceeded $450 million and 2025 growth stayed triple-digit.
  • Consultmed referrals launched in March 2026, expanding GP-sourced Juniper demand.

What critics are saying

  • Hims & Hers bought Eucalyptus on 2026-02-19, ending standalone employer upside.
  • Earnouts through early 2029 tie employee value to Hims & Hers targets.
  • Telehealth weight-loss rivals and regulators can crush Juniper margins quickly.

What makes Eucalyptus unique

  • Juniper and Pilot give Eucalyptus category-specific consumer brands across five countries.
  • Tim Doyle built local regulatory playbooks, enabling Hims & Hers' June 2026 integration.
  • ACHS accreditation and 20+ outcome studies signal clinically disciplined operations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Employee Stock Purchase Plan

Flexible Work Hours

Hybrid Work Options

Wellness Program

Mental Health Support

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Stock Options

Company Equity

Conference Attendance Budget

Professional Development Budget

Birthdays?

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

3%

2 year growth

-3%
Schaeffer's Investment Research
Feb 20th, 2026
Geopolitical Tensions Resurface Amid Volatile Week

Geopolitical tensions resurface amid volatile week. The S&P 500 and Nasdaq boast healthy weekly gains. Assistant Editor Feb 20, 2026 at 2:09 PM Despite Tuesday's rough start, all three major indexes closed higher, the Nasdaq Composite (IXIC) snapping its four day-losing streak. Stocks held steady on Wednesday after receiving a boost from big tech gains, while the Federal Reserve's January meeting minutes held investor attention. On Thursday, the Dow Jones Industrial Average (DJI) and S&P 500 Index (SPX) both snapped three-day win streaks, while the Nasdaq also faced trouble; these losses slid right past traders as focus remained on geopolitical tensions and weekly jobless claims. The Nasdaq and S&P 500 are pacing for weekly gains, after the Supreme Court dismissed President Donald Trump's tariffs and lifted Wall Street's spirits. Stock movers this week. There were plenty of headlines for investors to unpack over the holiday-shortened week. Norwegian Cruise Line Holdings (NCLH) popped after reports that Elliott Investment Management has built an over 10% stake. In M&A news, Masimo (MASI) stock soared after reports that it will be acquired by Danaher (DHR) for $10 billion, while Hims & Hers Health (HIMS) announced its $1.15 billion acquisition of Australian digital health company Eucalyptus. In biotech news this week, the U.S. Food & Drug Administration (FDA) accepted Moderna's (MRNA) flu vaccine application for review, while Grail (GRAL) stock plummeted after the company's three-year cancer screening trial failed to meet its main goal. Meanwhile, Walmart's (WMT) disappointed earnings outlook contributed to pessimism on Thursday. Commodities, rare earths in focus. Rising oil prices were a highlight this week amid U.S.-Iran tensions, with options bulls targeting the United States Oil Fund (USO). Meanwhile, Devon Energy (DVN) tapped a 17-month high after strong fourth-quarter results, while Melius Research upgraded Chevon (CVX), citing exploration upside. Even further, gold mining name Newmont (NEM) continued to charge higher before its fourth-quarter report. On the flip side, rare earths stock MP Materials (MP) plummeted to a one-month low. As goes february. The final week of the month is jam packed with key earnings reports, delayed economic data, speeches from several Federal Reserve officials, and more. For now, Schaeffer's Senior V.P. of Research Todd Salamone says to keep your eye on these S&P 500 names, while Senior Quantitative Analyst Rocky White breaks down Wall Street's "fear gauge."

The Wall Street Journal
Feb 19th, 2026
Hims & Hers to Acquire Eucalyptus in $1.15 Billion Deal

Hims & Hers Health has agreed to acquire digital health company Eucalyptus in a deal valued at $1.15 billion in an effort to expand its geographic reach.

Investing.com
Feb 19th, 2026
Hims & Hers stock rises after agreement to acquire Eucalyptus

Hims & Hers stock rises after agreement to acquire Eucalyptus. ByInvesting.com Published 02/19/2026, 06:54 AM (C) Reuters. Investing.com - Hims & Hers Health, Inc. (NYSE:HIMS) stock rose 7.8% Thursday morning after the company announced it has entered into a definitive agreement to acquire Eucalyptus, an international digital health leader with operations in Australia, the UK, Germany, Japan, and Canada. The acquisition, valued at up to $1.15 billion USD, will accelerate Hims & Hers' global expansion strategy while preserving its financial flexibility. The company will pay approximately $240 million in cash upon closing, with the remaining consideration structured as deferred payments over 18 months and additional earnout payments tied to financial targets through early 2029. Eucalyptus, which operates consumer brands including Juniper and Pilot, has served more than 775,000 customers and currently maintains an annual revenue run-rate exceeding $450 million USD. The company has demonstrated triple-digit YoY revenue growth in each quarter of calendar year 2025 while operating near profitability. "Healthcare challenges are global, and so is the demand for simpler, transparent, and more personalized healthcare," said Andrew Dudum, founder and CEO of Hims & Hers. "With Eucalyptus, we will not only enter new markets, we will expand our ability to serve customers globally, trusting local experts to be a key part of how we transform healthcare into a customer-first, personalized industry." Following the acquisition's completion, Eucalyptus CEO Tim Doyle will become SVP of International at Hims & Hers, overseeing the company's international business. Eucalyptus' portfolio of brands will transition into Hims & Hers over time. The transaction is expected to close during the middle of calendar year 2026, subject to regulatory approvals and other customary closing conditions. Hims & Hers plans to finance most of the acquisition using existing cash and future operating cash flows from its U.S. operations. Which stock should you buy in your very next trade? AI computing powers are changing the stock market. Investing.com's ProPicks AI includes dozens of winning stock portfolios chosen by our advanced AI. Year to date, 2 out of 3 global portfolios are beating their benchmark indexes, with 88% in the green. Our flagship Tech Titans strategy doubled the S&P 500 within 18 months, including notable winners like Super Micro Computer (+185%) and AppLovin (+157%). Which stock will be the next to soar?

PR Newswire
Jul 28th, 2025
Amigo Partners with Eucalyptus to Scale AI-Powered Healthcare Delivery Across Global Telehealth Network

Amigo partners with Eucalyptus to scale ai-powered healthcare delivery across global telehealth network.

PR Newswire
Feb 4th, 2025
Lorikeet Secures $9M for AI Expansion

Lorikeet, an AI customer experience company, has secured an additional AUD 9 million in funding from Blackbird and existing investors, following a USD 5 million seed round last year. The funds will enhance Lorikeet's platform and expand its market presence in industries like healthcare and finance. Lorikeet's intelligent graph technology enables AI agents to handle complex support queries, improving customer satisfaction and support efficiency for clients like Eucalyptus and Magic Eden.